Honedra (LSTA12) / Lisata Therapeutics - LARVOL DELTA

Study to Assess the Efficacy and Safety of CLBS12 in Patients With Critical Limb Ischemia (CLI) (clinicaltrials.gov) - P2 | N=33 | Completed | Sponsor: Caladrius Biosciences, Inc. | Active, not recruiting ➔ Completed

Trial completion • Atherosclerosis • Cardiovascular • Dyslipidemia • Peripheral Arterial Disease

Study to Assess the Efficacy and Safety of CLBS12 in Patients With Critical Limb Ischemia (CLI) (clinicaltrials.gov) - P2; N=35; Active, not recruiting; Sponsor: Caladrius Biosciences, Inc.; Recruiting ➔ Active, not recruiting; Trial completion date: Jun 2021 ➔ May 2022; Trial primary completion date: Jan 2021 ➔ May 2022

Clinical • Enrollment closed • Trial completion date • Trial primary completion date • Atherosclerosis • Cardiovascular • Dyslipidemia • Peripheral Arterial Disease

Study to Assess the Efficacy and Safety of CLBS12 in Patients With Critical Limb Ischemia (CLI) (clinicaltrials.gov) - P2; N=35; Recruiting; Sponsor: Caladrius Biosciences, Inc.; Trial completion date: Jul 2020 ➔ Jun 2021; Trial primary completion date: Jan 2020 ➔ Jan 2021

Clinical • Trial completion date • Trial primary completion date

"$CLBS EMA Grants Advanced Therapy Medicinal Product Classification for CLBS12, its CD34+ Cell Therapy for Critical Limb Ischemia" (,@BioStocks)